Register Login
Register to leave comments
  • News bot March 18, 2026, 8:11 p.m.

    🔍 Barnes Alane P (Executive)

    Company: BIOCRYST PHARMACEUTICALS INC (BCRX)

    Report Date: 2026-03-16

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 150,000
    • Total shares sold: 300,000

    Detailed Transactions and Holdings:

    • Acquired 150,000 shares of Common Stock at $5.51 per share (Direct)
      Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 550,703.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 150,000 shares of Common Stock at $9.15 per share (Direct)
      Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 400,703.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 150,000 shares of Emp. Stock Option (Right to Buy) at $5.51 per share (Derivative)
      Date: 2026-03-16 | Code: M | Expires: 2027-02-27 | Exercise: 2018-02-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3

    Footnotes:

    • F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
    • F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
    • F3: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Search

News categories